IGF2BP3 has been reported to be upregulated in many types of tumors, including pancreatic cancer,33 lung adenocarcinoma,34 triple‐negative breast cancer,35 colorectal cancer,36 hepatocellular carcinoma,37 and gliomas,38 suggesting that IGF2BP3 can serve as a novel cancer biomarker for early diagnosis and prognosis. This evidence concerns the gene IGF2BP3 and cancer.